Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Two-part, Randomized, Placebo-controlled, Observer-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in BCG Vaccinated, HIV-negative Subjects

NCT05547464 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT05547464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05547464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Two-part, Randomized, Placebo-controlled, Observer-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in BCG Vaccinated, HIV-negative Subjects
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 31, 2023
Completion date
January 31, 2027
Enrollment
497 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis